AMD

Retina specialists help educate the public to take steps to protect their vision during AMD Awareness Month.

Rishi Singh, MD, presented data from the Phase 3 DERBY and OAKS clinical trials for geographic atrophy at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.

In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”

In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 meeting hosted by Bascom Palmer Eye Institute, Baruch Kupperman, MD, PhD, detailed research in which investigators evaluated risuteganib for safety and effectiveness in patients with dry AMD.

In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.

In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.

A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.

According to investigators, the new discovery enhances our understanding of the previously unknown function of genomic regions outside the genes.

According to the company, the approval allows Eyenuk’s EyeArt AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss.

Researchers used obesity as a model to accelerate and exaggerate the stressors experienced by the body throughout life.

When dietary patterns were adjusted to include a Mediterranean diet, dietary nitrate intake was not associated with AMD progression independently.

Korean biotech company MDimune Inc. and scientists from the Clear Vision Research Lab at The Australian National University hope to turn recent research milestones into potential treatments for AMD.

The study, co-led by Griffith University’s Menzies Health Institute and South Korea’s Center for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technology, aims to understand how SARS-CoV-2 affects the eyes and whether it could serve as a virus infection route.

The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with geographic atrophy secondary to AMD that addresses the underlying causes of the disease.

According to physician, this therapeutic may prove to be a treatment option for these diseases.

The company is currently developing sustained release ophthalmic therapeutics aimed at reducing the frequency of intravitreal injections required to treat a wide range of retinal diseases.

David Eichenbaum, MD, FASRS, shared difficult cases of diabetic macular edema (DME) and age-related macular degeneration (AMD) and insights into patient care.

OPT-302 in combination with standard-of-care anti-VEGF-A agents shown to improve visual acuity, anatomic endpoints.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

In a real-world setting, eyes with AMD with a relatively good initial best-corrected visual acuity and no fibrovascular pigment epithelial detachment sustained or improved BCVA after anti-VEGF therapy within 3 years of follow-up.

Carl Danzig, MD, points out that the sooner patients can be diagnosed, the sooner ophthalmologists can treat them and preserve their vision.

The company noted that testing of a commercial supply of the implants, which included exposing them to multiple punctures with a needle, found they did not meet their standards. The company has notified the FDA, and is working with the agency on the recall process.

According to data released at the American Academy of Ophthalmology's 2022 annual meeting, a large number of wet AMD patients do not return for treatment.